Delivering AAV to the Central Nervous and Sensory Systems
- 13 April 2021
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 42 (6) , 461-474
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 119 references indexed in Scilit:
- Long-term, efficient inhibition of microRNA function in mice using rAAV vectorsNature Methods, 2012
- Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 MutationsArchives of Ophthalmology (1950), 2012
- Engineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene TransferMolecular Therapy, 2011
- Novel Properties of Tyrosine-mutant AAV2 Vectors in the Mouse RetinaMolecular Therapy, 2011
- Gene therapy in the second eye of RPE65-deficient dogs improves retinal functionGene Therapy, 2010
- Inner Limiting Membrane Barriers to AAV-mediated Retinal Transduction From the VitreousMolecular Therapy, 2009
- Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor NeuronsMolecular Therapy, 2009
- High-efficiency Transduction of the Mouse Retina by Tyrosine-mutant AAV Serotype VectorsMolecular Therapy, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower dosesProceedings of the National Academy of Sciences, 2008